Skip to main content
HRES 161 113th Congress House Health Drug safety, medical device, and laboratory regulation Drug, alcohol, tobacco use Prescription drugs

Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

Introduced: April 15, 2013 Introduced by: Rogers, Harold Republican · Kentucky See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 19, 2013
Referred to the Subcommittee on Health.
Apr 15, 2013
Referred to the House Committee on Energy and Commerce.
Apr 15, 2013
Introduced in House
 Plain-English summary Congressional Research Service

Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

What's happening now April 19, 2013

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2
 Cosponsors 3
All 3 Democratic 2 Republican 1